Unmet Needs in EGFR Exon 20 NSCLC and Next-Generation Oral TKIs

This episode, "Unmet Needs in EGFR Exon 20 NSCLC and Next-Generation Oral TKIs," features Dr. Yu examining the gaps that current first-line regimens leave open.

Dr. Yu notes that every current first-line regimen for exon 20 insertion-positive disease is given intravenously or subcutaneously. Each requires clinic visits for administration, which adds healthcare utilization costs. Treatment-related toxicities add further expense, including co-pays for supportive medications and visits to specialists such as dermatology. She emphasizes that effective therapy also reduces disease-related complications, which carry their own physical, emotional, and financial burden.

She is encouraged by oral targeted therapies moving through development. Patients stable on an oral regimen typically see her only every 3 months, a cadence that lowers utilization. She acknowledges that novel oral agents, like current infused options, come at a cost. Even so, she views efficacy as the key lever for controlling overall costs. Dr. Yu also flags a high incidence of metastases to the brain, spinal cord, and leptomeninges in this population. Because CNS disease drives substantial morbidity and mortality, CNS efficacy will be an important point of comparison.

Dr. Yu then explains why dedicated agents for EGFR mutations are needed. Osimertinib is the standard targeted therapy for common sensitizing mutations such as EGFR L858R and exon 19 deletions. Osimertinib or earlier-generation inhibitors such as afatinib may be used for atypical mutations. None of these are effective against exon 20 insertions. Two exon 20-specific inhibitors are furthest along in development. Sunvozertinib holds a US approval after chemotherapy but is currently unavailable because of manufacturing issues.

Zipalertinib is an oral inhibitor that binds the mutant receptor irreversibly through a distinct pyrrolopyrimidine structure. It has a lower IC50 against exon 20 insertions. Older inhibitors such as osimertinib reach exon 20 only at high doses, which also inhibit wild-type EGFR. Zipalertinib was designed to widen the therapeutic window between those two targets.

In "REZILIENT3: First-Line Zipalertinib Plus Chemotherapy in EGFR Exon 20 NSCLC," Dr. Yu walks through the design, efficacy, and safety findings of the phase 3 trial that tested this agent with chemotherapy in untreated patients.